TY - JOUR
T1 - Successful completion of pregnancy in a patient with chronic myeloid leukemia without active intervention
T2 - a case report and review of the literature.
AU - Cole, Suzanne
AU - Kantarjian, Hagop
AU - Ault, Patricia
AU - Cortés, Jorge E.
N1 - Funding Information:
Drs. Cortés and Kantarjian have received research support from Bristol-Myers Squibb Company and Novartis Pharmaceuticals Corporation. Drs. Ault and Cole have no relevant financial interests to report.
PY - 2009/8
Y1 - 2009/8
N2 - The management of patients with chronic myeloid leukemia (CML) during pregnancy is a matter of continued debate. We present a 21-year-old woman in whom CML was diagnosed during early pregnancy. Because the patient was asymptomatic and desired to carry the pregnancy to term while minimizing fetal exposure to medication, she was observed with no therapy for the duration of her pregnancy. The white blood cell count showed a slow downward trend throughout her pregnancy. She delivered a healthy baby and breast fed for a time before initiating therapy for CML. We reviewed the published case reports of women who had a pregnancy occur in the setting of treatment with imatinib. Given the adverse effects of fetal exposure to imatinib as treatment for the mother with CML, close observation might be an option for selected patients who are diagnosed with CML while pregnant and who have minimal clinical manifestations of CML.
AB - The management of patients with chronic myeloid leukemia (CML) during pregnancy is a matter of continued debate. We present a 21-year-old woman in whom CML was diagnosed during early pregnancy. Because the patient was asymptomatic and desired to carry the pregnancy to term while minimizing fetal exposure to medication, she was observed with no therapy for the duration of her pregnancy. The white blood cell count showed a slow downward trend throughout her pregnancy. She delivered a healthy baby and breast fed for a time before initiating therapy for CML. We reviewed the published case reports of women who had a pregnancy occur in the setting of treatment with imatinib. Given the adverse effects of fetal exposure to imatinib as treatment for the mother with CML, close observation might be an option for selected patients who are diagnosed with CML while pregnant and who have minimal clinical manifestations of CML.
UR - http://www.scopus.com/inward/record.url?scp=70350410861&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70350410861&partnerID=8YFLogxK
U2 - 10.3816/CLM.2009.n.064
DO - 10.3816/CLM.2009.n.064
M3 - Article
C2 - 19717385
AN - SCOPUS:70350410861
VL - 9
SP - 324
EP - 327
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
SN - 2152-2650
IS - 4
ER -